Edition:
United States

Orexigen Therapeutics Inc (OREX.OQ)

OREX.OQ on NASDAQ Stock Exchange Global Select Market

2.97USD
4:00pm EDT
Change (% chg)

$0.03 (+1.02%)
Prev Close
$2.94
Open
$2.92
Day's High
$3.03
Day's Low
$2.92
Volume
13,514
Avg. Vol
76,806
52-wk High
$6.49
52-wk Low
$1.66

OREX.OQ

Chart for OREX.OQ

About

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management... (more)

Overall

Beta: 2.88
Market Cap(Mil.): $44.77
Shares Outstanding(Mil.): 15.23
Dividend: --
Yield (%): --

Financials

  OREX.OQ Industry Sector
P/E (TTM): -- 141.29 17.43
EPS (TTM): -6.78 -- --
ROI: -26.82 2.17 -5.41
ROE: -4,714.72 0.10 -4.69

BRIEF-Orexigen Therapeutics reports Q1 loss per share $4.67

* Orexigen Therapeutics reports financial results for the first quarter ended March 31, 2017

May 09 2017

BRIEF-Navamedic signs deal with Orexigen Therapeutics for Nordic launch of Mysimba

* NAVAMEDIC ASA: ENTERS INTO PARTNERSHIP AGREEMENT WITH OREXIGEN THERAPEUTICS FOR NORDIC LAUNCH OF MYSIMBA®

May 02 2017

BRIEF-Orexigen Therapeutics announces new drug submission for Contrave in Canada

* Orexigen Therapeutics Inc announces new drug submission for Contrave© in canada

Apr 25 2017

BRIEF-Orexigen Therapeutics on March 28, 2017, entered into controlled equity offering sales agreement

* Orexigen Therapeutics Inc- on March 28, 2017, entered into a controlled equity offering sales agreement - sec filing

Mar 30 2017

BRIEF-Orexigen Therapeutics reports Q4 loss per share $1.69

* Orexigen Therapeutics reports financial results for the fourth quarter and year ended December 31, 2016

Mar 28 2017

BRIEF-Orexigen Therapeutics sees Q4 total revenue $13.4-$13.9 mln

* Orexigen Therapeutics Inc - Expects total revenue for q4 of 2016 to be between approximately $13.4 million to $13.9 million

Feb 17 2017

More From Around the Web

Earnings vs. Estimates